|
시장보고서
상품코드
2084762
기저세포암 시장 : 치료법별, 최종사용자별, 지역별Basal Cell Carcinoma Market, By Treatment Type, By End User, By Geography |
||||||
기저세포암 시장은 2026년에 42억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 81억 5,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 42억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 9.80% | 2033년 시장 규모 예측 : | 81억 5,000만 달러 |
기저세포암은 피부암의 일종입니다. 기저세포암은 오래된 피부 세포가 죽어감에 따라 새로운 피부 세포를 생성하는 피부 내의 일종의 세포인 기저세포에서 발생합니다. 기저세포암은 대부분의 경우 피부 표면에 약간 투명한 융기 형태로 나타나지만, 다른 형태를 띠기도 합니다. 기저세포암은 머리나 목 등 햇빛에 노출되는 피부 부위에서 가장 흔히 발생합니다. 햇빛에 노출되는 피부가 하얀 사람들에게서 흔히 나타나며, 피부색이 어두운 사람들에게서는 매우 드뭅니다.
시장 역학
전 세계 기저세포암 시장에서 사업을 운영하는 주요 기업은 신제품 출시, 규제 당국의 승인, 기저세포암 치료를 위한 연구개발 등 성장 전략을 채택하는 데 주력하고 있으며, 이러한 요소들이 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2021년 1월, 암 및 섬유화 질환에 대한 RNAi 치료제의 발견 및 개발을 담당하는 바이오의약품 기업인 Sirnaomics, Inc.는 피부 기저세포암 치료를 목적으로 하는 자사의 주력 후보 약물 'STP705'의 2a상 임상시험에서 첫 번째 환자에 대한 투여를 시작했다고 발표했습니다. 또한 2021년 11월 18일, 의학적 개입이 필요한 피부 질환 치료제를 개발하고 있는 피부과 치료제 기업인 Verrica Pharmaceuticals Inc.는 기저세포암 치료를 목적으로 하는 ‘퍼스트-인-클래스’가 될 가능성이 있는 종양 용해성 펩티드 ‘ LTX-315'에 대한 임상시험용 의약품 신청서를 미국 식품의약국(FDA)이 접수했다고 발표했습니다. 이 회사는 2022년 1분기에 기저세포암을 대상으로 한 LTX-315의 2상 임상시험을 시작할 전망입니다.
본 연구의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 보고서에서는 다음의 주요 항목(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)을 바탕으로 전 세계 기저세포암 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 기저세포암 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 기저세포암 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 기저세포암 시장 : 치료 유형별, 2021-2033년
제5장 세계의 기저세포암 시장 : 최종사용자별, 2021-2033년
제6장 세계의 기저세포암 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.14Basal Cell Carcinoma Market is estimated to be valued at USD 4.2 Bn in 2026 and is expected to reach USD 8.15 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 8.15 Bn |
Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells a type of cell within the skin that produces new skin cells as old ones die off. Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. It is more common among fair-skinned people with sun exposure and is very rare among dark-skinned people.
Market Dynamics
Key players operating in the global basal cell carcinoma market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of basal cell carcinoma, which is expected to drive the market growth during the forecast period. For instance, in January 2021, Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. Moreover, in November 18 2021, Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that the U.S. Food and Drug Administration had accepted the company's investigational new drug application for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The company expects to initiate its phase II trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global basal cell carcinoma market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global basal cell carcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal cell carcinoma market
Market Segmentation
- By Treatment Type (Revenue, USD Bn, 2021-2033)
- Surgical
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Topical Treatment
- Advanced Medication
- Other
- Others
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
- By End User (Revenue, USD Bn, 2021-2033)
- Hospitals
- Specialty Clinics
- Others
- Global Basal Cell Carcinoma Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG.
- Bausch & Lomb Incorporated.
- Allergan
- Perrigo Company plc
- Taro Pharmaceutical Industries Ltd.
- Provectus Biopharmaceuticals, Inc.
- Hoffmann-La Roche Ltd
- Sanofi
- Mylan N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Basal Cell Carcinoma Market, By Treatment Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Segment Trends
- Surgical Excision
- Electrodessication & Cutterage ED&C
- Moh's Surgery
- Cryosurgery
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Segment Trends
- Topical Treatment
- Advanced Medication
- Other
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Segment Trends
- Radiation Therapy
- Photodynamic Therapy PDT
- Laser Therapy
5. Global Basal Cell Carcinoma Market, By End User, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Basal Cell Carcinoma Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bausch & Lomb Incorporated.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Perrigo Company plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Taro Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Provectus Biopharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
